The present invention relates to compounds of the general formula <；CHEM>； wherein R is hydrogen, lower alkyl, lower alkoxy, halogen or trifluoromethyl； R<；1>； is hydrogen or halogen； or R and R<；1>； may be together -CH=CH-CH=CH-； R<；2>； and R<；2'>； are independently from each other hydrogen, halogen, trifluoromethyl, lower alkoxy or cyano； or R<；2>； and R<；2'>； may be together -CH=CH-CH=CH-, optionally substituted by one or two substituents selected from lower alkyl or lower alkoxy； R<；3>； is hydrogen, lower alkyl or form a cycloalkyl group； R<；4>； is hydrogen, -N(R<；5>；)2, -N(R<；5>；)(CH2)nOH, -N(R<；5>；)S(O)2-lower alkyl, -N(R<；5>；)S(O)2-phenyl, -N=CH-N(R<；5>；)2, -N(R<；5>；)C(O)R<；5>； or a cyclic tertiary amine of the group <；CHEM>； R<；5>； is, independently from each other, hydrogen, C3-6-cycloalkyl, benzyl or lower alkyl； R<；6>； is hydrogen, hydroxy, lower alkyl, -(CH2)nCOO-lower alkyl, -N(R<；5>；)CO-lower alkyl, hydroxy-lower alkyl, cyano, -(CH2)nO(CH2)nOH, -CHO or a 5-or 6 membered heterocyclic group, optionally bonded via an alkylene group, X is -C(O)N(R<；5>；)-, -(CH2)mO-, -(CH2)mN(R<；5>；)-, -N(R<；5>；)C(O)-, or -N(R<；5>；)(CH2)m-； n is 0-4； and m is 1 or 2； and to pharmaceutically acceptable acid addition salts thereof. The compounds of formula I show a high affinity to the NK- 1 receptor. They may be used for the treatment of diseases, which relate to NK- 1 receptor antagonists.
